Trial Profile

CKDB-501 for Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 10 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Botulinum toxin (Primary)
Indications Major depressive disorder; Post-traumatic stress disorders; Social phobia
Focus Therapeutic Use

04 Aug 2026 According to Healis Therapeutics media release, the company has opened an IND with the U.S. FDA. The milestone enables Healis to initiate its U.S. clinical trial The Phase 1 single-ascending-dose study will evaluate Tyemvers safety and tolerability. Completion is expected to support Phase 2 studies in major depressive disorder, post-traumatic stress disorder, and social anxiety disorder.
26 Mar 2024 According to Healis Therapeutics media release, company announced that it has entered a clinical collaboration with Massachusetts General Hospital (MGH)
04 Jan 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com